Taspoglutide
Encyclopedia
Taspoglutide is a pharmaceutical drug. It is a glucagon-like peptide-1 analog
, under investigation for treatment of type 2 diabetes being codeveloped by Ipsen
and Roche.
Two phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide
, sitagliptin
, insulin glargine
, and pioglitazone
), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)
As of September 2010, Roche had halted Phase III clinical trials due to a incidences of serious hypersensitivity reactions and gastrointestinal side effects.
In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
Glucagon-like peptide-1 analog
Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes.One of their advantages is that they have a lower risk of causing hypoglycemia.Licenced : exenatide , liraglutide...
, under investigation for treatment of type 2 diabetes being codeveloped by Ipsen
Ipsen
Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. In 2005, Ipsen spent € 169 million—20.9% of consolidated sales—on research and development, according...
and Roche.
Two phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide (four against exenatide
Exenatide
Exenatide is a medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals and Eli Lilly and Company....
, sitagliptin
Sitagliptin
Sitagliptin is an oral antihyperglycemic of the dipeptidyl peptidase-4 inhibitor class. It was developed, and is marketed, by Merck & Co...
, insulin glargine
Insulin glargine
Insulin glargine, marketed by Sanofi-Aventis under the name Lantus, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours,...
, and pioglitazone
Pioglitazone
Pioglitazone is a prescription drug of the class thiazolidinedione with hypoglycemic action.Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda...
), at least five were active in 2009. Preliminary results in early 2010 were favourable. (At least one of the eight planned phase III trials had not started recruiting by end 2009.)
As of September 2010, Roche had halted Phase III clinical trials due to a incidences of serious hypersensitivity reactions and gastrointestinal side effects.
Chemistry
Taspoglutide is the peptide with the sequence H2N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH2.In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.
See also
- Glucagon-like peptide-1 analogGlucagon-like peptide-1 analogGlucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes.One of their advantages is that they have a lower risk of causing hypoglycemia.Licenced : exenatide , liraglutide...
s:
- exenatideExenatideExenatide is a medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals and Eli Lilly and Company....
(Byetta) - liraglutideLiraglutideLiraglutide , marketed under the brand name Victoza, is a long-acting glucagon-like peptide-1 analog that has been developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency on July 3, 2009, and by the U.S...
(Victoza) - albiglutideAlbiglutideAlbiglutide is a GLP-1 analog drug under investigation by GlaxoSmithKline for treatment of type 2 diabetes.It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin....
- DPP4 inhibitors
- IncretinIncretinIncretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by...